{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T00:03:06Z","timestamp":1790640186059,"version":"4.1.0"},"reference-count":32,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jocn-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Neuroscience"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.jocn.2026.112114","type":"journal-article","created":{"date-parts":[[2026,5,31]],"date-time":"2026-05-31T08:59:59Z","timestamp":1780217999000},"page":"112114","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Optimal duration of dual antiplatelet therapy for secondary stroke prevention: A systematic review and meta-analysis"],"prefix":"10.1016","volume":"151","author":[{"given":"Andr\u00e9 Richard da Silva","family":"Oliveira Filho","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nat\u00e1lia Vasconcellos","family":"de Oliveira Souza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel Macedo de","family":"Oliveira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jo\u00e3o Vitor Andrade","family":"Fernandes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9 de S\u00e1","family":"Braga Oliveira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julyana Medeiros","family":"Dantas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gisele Sampaio","family":"Silva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jocn.2026.112114_b0005","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1161\/STROKEAHA.120.031792","article-title":"Whole-genome sequencing association analyses of stroke and its subtypes in ancestrally diverse populations from trans-omics for precision medicine project","volume":"53","author":"Hu","year":"2022","journal-title":"Stroke"},{"key":"10.1016\/j.jocn.2026.112114_b0010","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1056\/NEJMoa1800410","article-title":"Clopidogrel and aspirin in acute ischemic stroke and high-risk TIA","volume":"379","author":"Johnston","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jocn.2026.112114_b0015","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1056\/NEJMoa1916870","article-title":"Ticagrelor and aspirin or aspirin alone in acute ischemic stroke or TIA","volume":"383","author":"Johnston","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jocn.2026.112114_b0020","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1215340","article-title":"Clopidogrel with aspirin in acute minor stroke or transient ischemic attack","volume":"369","author":"Wang","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jocn.2026.112114_b0025","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000209907","article-title":"Duration of dual antiplatelet therapy in acute transient ischemic attack or mild ischemic stroke: are we settled with 21 days?","volume":"103","author":"Li","year":"2024","journal-title":"Neurology"},{"key":"10.1016\/j.jocn.2026.112114_b0030","doi-asserted-by":"crossref","first-page":"2413","DOI":"10.1056\/NEJMoa2309137","article-title":"Dual Antiplatelet treatment up to 72 hours after ischemic stroke","volume":"389","author":"Gao","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jocn.2026.112114_b0035","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1001\/jamaneurol.2019.2531","volume":"76","author":"Pan","year":"2019","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.jocn.2026.112114_b0040","article-title":"Clopidogrel plus aspirin versus aspirin alone for acute minor ischaemic stroke or high risk transient ischaemic attack: systematic review and meta-analysis","volume":"363","author":"Hao","year":"2018","journal-title":"BMJ"},{"key":"10.1016\/j.jocn.2026.112114_b0045","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2025.1516402","article-title":"Tailoring dual antiplatelet therapy for stroke prevention: a meta-analysis of timing, duration, regimen, and stroke subtypes","volume":"16","author":"Alhawiti","year":"2025","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.jocn.2026.112114_b0050","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1016\/S0140-6736(17)30770-5","article-title":"Age-specific risks, severity, time course, and outcome of bleeding on long-term antiplatelet treatment after vascular events: a population-based cohort study","volume":"390","author":"Li","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.jocn.2026.112114_b0055","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1111\/ene.12982","article-title":"Dual antiplatelet therapy after stroke or transient ischaemic attack - how long to treat? the duration of aspirin plus clopidogrel in stroke or transient ischaemic attack: a systematic review and meta-analysis","volume":"23","author":"Ge","year":"2016","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.jocn.2026.112114_b0060","doi-asserted-by":"crossref","first-page":"2575","DOI":"10.1161\/CIRCULATIONAHA.109.895342","article-title":"Bleeding complications with dual antiplatelet therapy among patients with stable vascular disease or risk factors for vascular disease","volume":"121","author":"Berger","year":"2010","journal-title":"Circulation"},{"key":"10.1016\/j.jocn.2026.112114_b0065","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1136\/svn-2016-000008","article-title":"Dual antiplatelet therapy may increase the risk of non-intracranial haemorrhage in patients with minor strokes: a subgroup analysis of the CHANCE trial","volume":"1","author":"Wang","year":"2016","journal-title":"Stroke Vasc Neurol"},{"key":"10.1016\/j.jocn.2026.112114_b0070","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1111\/ene.13695","article-title":"Efficacy and safety of dual antiplatelet therapy in the elderly for stroke prevention: a systematic review and meta-analysis","volume":"25","author":"Ding","year":"2018","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.jocn.2026.112114_b0075","unstructured":"Higgins JP, Thomas J, Chandler J, Cumpston M, Li T, Page MJ, et al. Cochrane Handbook for Systematic Reviews of Interventions version 6.5. Cochrane; 2024."},{"key":"10.1016\/j.jocn.2026.112114_b0080","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.jocn.2026.112114_b0085","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1161\/STROKEAHA.120.031329","article-title":"Clinical characteristics and in-hospital outcomes of varying definitions of minor stroke","volume":"52","author":"Xiong","year":"2021","journal-title":"Stroke"},{"key":"10.1016\/j.jocn.2026.112114_b0090","doi-asserted-by":"crossref","unstructured":"GUSTO investigators. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. N Engl J Med 1993;329:673\u201382. https:\/\/doi.org\/10.1056\/NEJM199309023291001.","DOI":"10.1056\/NEJM199309023291001"},{"key":"10.1016\/j.jocn.2026.112114_b0095","article-title":"Intervention meta-analysis: application and practice using R software","volume":"41","author":"Shim","year":"2019","journal-title":"Epidemiol Health"},{"key":"10.1016\/j.jocn.2026.112114_b0100","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ"},{"key":"10.1016\/j.jocn.2026.112114_b0105","doi-asserted-by":"crossref","first-page":"1906","DOI":"10.1212\/WNL.0000000000003941","article-title":"Risks and benefits of clopidogrel-aspirin in minor stroke or TIA: time course analysis of CHANCE","volume":"88","author":"Pan","year":"2017","journal-title":"Neurology"},{"key":"10.1016\/j.jocn.2026.112114_b0110","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1161\/CIRCULATIONAHA.119.040713","article-title":"Time course for benefit and risk of clopidogrel and aspirin after acute transient ischemic attack and minor ischemic stroke","volume":"140","author":"Johnston","year":"2019","journal-title":"Circulation"},{"key":"10.1016\/j.jocn.2026.112114_b0115","doi-asserted-by":"crossref","first-page":"e46","DOI":"10.1212\/WNL.0000000000200355","article-title":"Time course for benefit and risk of Ticagrelor and aspirin in acute ischemic stroke or transient ischemic attack","volume":"99","author":"Wang","year":"2022","journal-title":"Neurology"},{"key":"10.1016\/j.jocn.2026.112114_b0120","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000209845","article-title":"Duration of benefit and risk of dual antiplatelet therapy up to 72 hours after mild ischemic stroke and transient ischemic attack","volume":"103","author":"Guan","year":"2024","journal-title":"Neurology"},{"key":"10.1016\/j.jocn.2026.112114_b0125","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/S0140-6736(04)16721-4","article-title":"Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial","volume":"364","author":"Diener","year":"2004","journal-title":"Lancet"},{"key":"10.1016\/j.jocn.2026.112114_b0130","doi-asserted-by":"crossref","first-page":"1706","DOI":"10.1056\/NEJMoa060989","article-title":"Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events","volume":"354","author":"Bhatt","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jocn.2026.112114_b0135","doi-asserted-by":"crossref","unstructured":"ACTIVE Investigators, Connolly SJ, Pogue J, Hart RG, Hohnloser SH, Pfeffer M, et al. Effect of clopidogrel added to aspirin in patients with atrial fibrillation. N Engl J Med 2009;360:2066\u201378. https:\/\/doi.org\/10.1056\/NEJMoa0901301.","DOI":"10.1056\/NEJMoa0901301"},{"key":"10.1016\/j.jocn.2026.112114_b0140","doi-asserted-by":"crossref","unstructured":"SPS3 Investigators, Benavente OR, Hart RG, McClure LA, Szychowski JM, Coffey CS, et al. Effects of clopidogrel added to aspirin in patients with recent lacunar stroke. N Engl J Med 2012;367:817\u201325. https:\/\/doi.org\/10.1056\/NEJMoa1204133.","DOI":"10.1056\/NEJMoa1204133"},{"key":"10.1016\/j.jocn.2026.112114_b0145","doi-asserted-by":"crossref","unstructured":"ACTIVE Writing Group of the ACTIVE Investigators, Connolly S, Pogue J, Hart R, Pfeffer M, Hohnloser S, et al. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet 2006;367:1903\u201312. https:\/\/doi.org\/10.1016\/S0140-6736(06)68845-4.","DOI":"10.1016\/S0140-6736(06)68845-4"},{"key":"10.1016\/j.jocn.2026.112114_b0150","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1136\/svn-2023-002933","article-title":"Optimal duration of dual antiplatelet therapy for minor stroke within 72 hours of symptom onset: a prospective cohort study","volume":"10","author":"Liu","year":"2025","journal-title":"Stroke Vasc Neurol"},{"key":"10.1016\/j.jocn.2026.112114_b0155","doi-asserted-by":"crossref","first-page":"e05","DOI":"10.15420\/icr.2021.30","article-title":"Antithrombotic management in AF patients following percutaneous coronary intervention: a european perspective","volume":"18","author":"Greco","year":"2023","journal-title":"Interv Cardiol Lond Engl"},{"key":"10.1016\/j.jocn.2026.112114_b0160","doi-asserted-by":"crossref","DOI":"10.1161\/CIRCINTERVENTIONS.118.006853","article-title":"Prediction of ischemic and bleeding events using the dual antiplatelet therapy score in an unrestricted percutaneous coronary intervention population","volume":"11","author":"Brener","year":"2018","journal-title":"Circ Cardiovasc Interv"}],"container-title":["Journal of Clinical Neuroscience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0967586826002651?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0967586826002651?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T23:34:57Z","timestamp":1790638497000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0967586826002651"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":32,"alternative-id":["S0967586826002651"],"URL":"https:\/\/doi.org\/10.1016\/j.jocn.2026.112114","relation":{},"ISSN":["0967-5868"],"issn-type":[{"value":"0967-5868","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Optimal duration of dual antiplatelet therapy for secondary stroke prevention: A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Neuroscience","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jocn.2026.112114","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"112114"}}